Milestone Pharmaceuticals (NYSE: MIST) — Perfil da empresa, notícias e dados financeiros
Milestone Pharmaceuticals develops innovative cardiovascular medicines, focusing on treatments for heart conditions like PSVT.
Milestone Pharmaceuticals
Milestone Pharmaceuticals (NASDAQ:MIST) specializes in the development and commercialization of innovative cardiovascular medicines. Its primary focus is on creating treatments for heart conditions, notably its leading project, etripamil, a novel short-acting calcium channel blocker designed to be self-administered via nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT), a condition causing rapid heartbeat. The company aims to transform how heart-related episodes are managed, offering patients rapid relief in non-hospital settings. By advancing its pipeline with etripamil and exploring its potential in other cardiac indications, Milestone is committed to improving the lives of those with cardiovascular diseases, seeking to provide effective patient-centric therapies.
Resumo
Operações
Produtos e/ou serviços de Milestone Pharmaceuticals
- Etripamil, a novel, fast-acting nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT), designed for self-administration by patients to rapidly terminate episodes.
- Development of etripamil for additional indications beyond PSVT, potentially expanding its use in other cardiac conditions requiring rapid heart rate control.
- Research and development pipelines focusing on cardiovascular diseases, aiming to identify and progress novel candidates for arrhythmias and other related conditions.
- Partnership programs with other pharmaceutical companies to enhance the development and commercialization potential of etripamil and other pipeline projects.
- Investment in advanced drug delivery technologies to improve patient convenience and efficacy of current and future therapeutics.
- Initiatives to expand the geographical footprint of their flagship products, targeting new markets and regulatory approvals in Europe, Asia, and additional regions.
equipe executiva do Milestone Pharmaceuticals
- Joseph G. OlivetoCEO, President & Executive Director
- Amit HasijaCFO & Executive VP of Corporate Development
- David B. BharuchaChief Medical Officer
- Philippe DouvilleFounder, Strategic Advisor & Member of Scientific Advisory Board
- Jeffrey NelsonChief Operating Officer
- David SandovalGeneral Counsel & Chief Compliance Officer
- Roshan GirglaniVice President of Marketing
- Jeff MooreVice President of Sales
- Philip T. SagerChief Medical Advisor & Member of the Scientific Advisory Board
- Guy RousseauSVP of Regulatory Affairs and Quality Management
Principais indicadores financeiros
Resultados divulgados pela Milestone Pharmaceuticals, em USD.
- Cap. de mercado
- 94,3 mi
- Receita (TTM)
- 2,3 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,5 mi | -62,5 mi | -63,1 mi | |
| 0 | -42,1 mi | -41,5 mi | |
| 1 mi | -61,1 mi | -59,7 mi | |
| 5 mi | -59,6 mi | -57,1 mi |